Published in HIV AIDS (Auckl) on March 23, 2016
Immune Activation and Bacterial Translocation: A Link between Impaired Immune Recovery and Frequent Visceral Leishmaniasis Relapses in HIV-Infected Patients. PLoS One (2016) 0.75
Characterization of Leishmania (L.) infantum chagasi in visceral leishmaniasis associated with hiv co-infection in Northeastern Brazil. Rev Inst Med Trop Sao Paulo (2017) 0.75
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med (1998) 53.26
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med (2009) 21.74
The increase in risk factors for leishmaniasis worldwide. Trans R Soc Trop Med Hyg (2001) 6.02
Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev (1997) 4.09
Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health (2001) 3.08
Clinical characteristics and treatment outcome of patients with visceral leishmaniasis and HIV co-infection in northwest Ethiopia. Trop Med Int Health (2010) 2.62
Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy. Lancet (1998) 2.43
Leishmania/HIV co-infections: epidemiology in Europe. Ann Trop Med Parasitol (2003) 2.41
Visceral leishmaniosis in HIV-positive patients: primary infection, reactivation and latent infection. Impact of the CD4+ T-lymphocyte counts. AIDS (1998) 1.94
Leishmania/HIV co-infections in the second decade. Indian J Med Res (2006) 1.73
Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome. Clin Infect Dis (2008) 1.66
Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review. PLoS Negl Trop Dis (2011) 1.63
Leishmania-HIV co-infection: clinical presentation and outcomes in an urban area in Brazil. PLoS Negl Trop Dis (2014) 1.56
Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India. Clin Infect Dis (2011) 1.47
Visceral leishmaniasis and HIV in Tigray, Ethiopia. Trop Med Int Health (2003) 1.41
Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence. Clin Infect Dis (2011) 1.38
Prevalence of and factors associated with visceral leishmaniasis in human immunodeficiency virus type 1-infected patients in southern Spain. J Clin Microbiol (1998) 1.17
Antimony-resistant Leishmania donovaniin eastern Sudan: incidence and in vitro correlation. East Mediterr Health J (2003) 1.13
Visceral leishmaniasis in the New World & Africa. Indian J Med Res (2006) 1.11
Visceral Leishmaniasis and HIV coinfection in East Africa. PLoS Negl Trop Dis (2014) 1.09
Treatment of visceral leishmaniasis in 2004. Am J Trop Med Hyg (2004) 1.06
The pathogenesis of Leishmania/HIV co-infection: cellular and immunological mechanisms. Ann Trop Med Parasitol (2003) 1.06
Prevention of relapse after chemotherapy in a chronic intracellular infection: mechanisms in experimental visceral leishmaniasis. J Immunol (2005) 1.05
Comparison of parasitological, serological, and molecular tests for visceral leishmaniasis in HIV-infected patients: a cross-sectional delayed-type study. Am J Trop Med Hyg (2013) 1.02
Visceral leishmaniasis and HIV co-infection in Bihar, India: long-term effectiveness and treatment outcomes with liposomal amphotericin B (AmBisome). PLoS Negl Trop Dis (2014) 1.01
Leishmaniasis in HIV infection. J Postgrad Med (2003) 1.00
Risk factors for visceral leishmaniasis relapse in immunocompetent patients following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) in Bihar, India. PLoS Negl Trop Dis (2014) 1.00
Arginase activity in the blood of patients with visceral leishmaniasis and HIV infection. PLoS Negl Trop Dis (2013) 0.99
Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy. J Clin Microbiol (2002) 0.99
Role of Leishmania donovani and its lipophosphoglycan in CD4+ T-cell activation-induced human immunodeficiency virus replication. Infect Immun (1999) 0.97
Visceral leishmaniasis and HIV coinfection in Latin America. PLoS Negl Trop Dis (2014) 0.92
Human immunodeficiency virus/Leishmania infantum in the first foci of urban American visceral leishmaniasis: clinical presentation from 1994 to 2010. Rev Soc Bras Med Trop (2013) 0.88
Effect of highly active antiretroviral therapy on the incidence and clinical manifestations of visceral leishmaniasis in human immunodeficiency virus-infected patients. Clin Infect Dis (2003) 0.87
Frequency of visceral leishmaniasis relapses in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy. Am J Trop Med Hyg (2004) 0.87
HIV/AIDS-related visceral leishmaniasis: a clinical and epidemiological description of visceral leishmaniasis in northern Brazil. Rev Soc Bras Med Trop (2014) 0.83
Combination Treatment for Visceral Leishmaniasis Patients Coinfected with Human Immunodeficiency Virus in India. Clin Infect Dis (2015) 0.81